Table 1.
Baseline characteristics of the studies in the meta-analysis
| Studies (reference) | Year | Country | Treatment | Sample size (male, n) | Mean/median ages (years) | Vascular invasion (yes) | Differentiation (I,II/III,IV,n) |
|---|---|---|---|---|---|---|---|
| Shirakawal
[18] |
2009 |
Japan |
SR |
107(85) |
63.6/60.2 |
57 |
12/95 |
| Yorita
[19] |
2010 |
Japan |
SR |
194(142) |
NA |
108 |
179/15 |
| Su
[20] |
2012 |
China |
SR |
61(55) |
48.0 |
NA |
NA |
| Yu
[21] |
2012 |
Taiwan |
SR |
100(90) |
51.39 |
23 |
NA |
| Wang
[23] |
2012 |
China |
LT |
31(29) |
49 |
16 |
6/25 |
| Chen
[24] |
2013 |
Japan |
SR |
55(36) |
65.5 /63.5 |
NA |
NA |
| Fu
[25] |
2013 |
China |
SR |
160(140) |
50.2 |
30 |
123/37 |
| Liang
[26] |
2013 |
China |
SR |
362(324) |
43-50 |
53 |
NA |
|
Studies (Reference) |
Tumor stage (I,II/III,IV,n) |
Follow-up Mean/median (months) |
Outcome indexes |
Multi-variate analysis |
Patients with High GPC3 |
Study quality (Points) |
"high" GPC3 cut-off level |
| Shirakawal
[18] |
92/15 |
42 |
OS/DFS |
Yes |
87 |
8/9 |
>10 % |
| Yorita
[19] |
82/112 |
31.2 |
OS/DFS |
Yes |
97 |
7/9 |
≥20 % |
| Su
[20] |
45/16 |
NA |
OS/DFS |
Yes |
32 |
5/9 |
>10 % |
| Yu
[21] |
NA |
66.5 |
DFS |
NA |
NA |
5/9 |
+3* |
| Wang
[23] |
12/19 |
24 |
DFS |
NA |
20 |
5/9 |
>10 % |
| Chen
[24] |
NA |
66 |
OS/DFS |
yes |
28 |
6/9 |
>10 % |
| Fu
[25] |
NA |
34.5 |
OS/DFS |
yes |
109 |
8/9 |
>25 % |
| Liang
[26] |
NA |
34.5 |
OS |
NA |
228 |
6/9 |
>0 % |
|
Studies (Reference) |
Antibody type |
Detection method |
Evaluation method |
GPC3 staining |
|||
| Shirakawal
[18] |
Mouse Monoclonal antibody |
IHC |
Positive area |
Cytoplasm membrane |
|||
| Yorita
[19] |
Monoclonal antibody |
IHC: Histofine Her2 kit |
Positive area |
Cytoplasm membrane |
|||
| Su
[20] |
Mouse Monoclonal antibody |
IHC: Chemmate EnVision/Mo&Rb detection kit |
Positive area and intensity |
Cytoplasm membrane |
|||
| Yu
[21] |
NA |
IHC |
NA |
Cytoplasm membrane |
|||
| Wang
[23] |
Monoclonal antibody |
IHC |
Positive area |
Cytoplasm membrane |
|||
| Chen
[24] |
Rabbit monoclonal antibody |
IHC |
Positive area |
cytoplasm peri- canalicular |
|||
| Fu
[25] |
Mouse Monoclonal antibody |
IHC |
Percentage of positive cells |
Cytoplasm membrane |
|||
| Liang [26] | NA | IHC: two-step protocol (DakoCytomation, Glostrup, Denmar) | TMAJ Image application | Cytoplasm membrane | |||
SR, surgical resection; LT, livertransplantation; NA, not available; IHC, immunohistochemistry; OS, overall survival; DFS, disease-free survival.
Tumor vascular invasion was defined as presence of either macro- or microscopic vascular invasion (including portal vein invasion, etc.).
High glypican-3 cut-off level was scored according to the percentage of positive tumor cells by immunohistochemical staining.
*The expression level was scored on a scale from -3 (underexpression) to +3 (overexpression).